Search - tctmd.com

Displaying 41 - 60 of 174

Sort: Relevancy | Date

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Conference News AHA 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

Todd Neale

November 12, 2023

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Caitlin E. Cox

November 11, 2022

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

L.A. McKeown

November 11, 2022

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

L.A. McKeown

November 09, 2022

Advertisement

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Safety and Pharmacodynamic Effects of VERVE-101

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

Sizeable Minority of Pregnant Women Have CVD, US Data Show

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

China Rural Intervention Still Reaping BP Control Wins at 3 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content